NCT05025813View on ClinicalTrials.gov

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2027

Conditions
Cutaneous Squamous Cell Carcinoma of the Head and NeckHead and Neck Cancer
Interventions
DRUG

Pembrolizumab

Delivery of neo-adjuvant Pembrolizumab

Trial Locations (3)

2050

RECRUITING

Chris O'Brien Lifehouse, Camperdown

4029

RECRUITING

Royal Brisbane and Women's Hospital, Herston

4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Queensland Health

OTHER_GOV